Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus SUPRAX.
KEFUROX IN PLASTIC CONTAINER vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic